Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Latest News

Rector of the University of Milan visiting Nerviano Campus Nerviano, January 23, 2015 – Prof. Gianluca Vago, Rector of the University of Milan, was today guest at the laboratories and facilities of NMS Group. “The visit - has declared the Rector - originates from the will to deepen the knowledge of a research and development company that already cooperates with the University and that maintains specific characteristics on the national... Read more
Nerviano Medical Sciences: new personalized treatments active on acute myeloid leukemia, gastrointestinal and female tumors, with innovative opportunities of dna repair processes EFFICACY IN LEUKEMIA WITH NO CARDIOTOXICITY OR ‘GATEKEEPER’ MUTATION RESISTANCE FOR NMS-P088. SEVERAL OPPORTUNITIES AMONG PARP-1 INHIBITORS, ACTIVE IN BREAST AND OVARY TUMORS WITH BRCA1 AND BRCA2 MUTATION. PRESENTED THE ESTABLISHMENT AND CHARACTERIZATION OF A CHORDOMA CELL LINE, RELEVANT FOR THE KNOWLEDGE OF THIS RARE CANCER AND THE RESEARCH OF NEW THERAPIES. Nerviano, April 21 2015 - Nerviano... Read more
SOT 2015: presented by Accelera and StemGen new data on treatment of glioblastoma, the most common brain tumor. UNDER STUDY TOXICITY AND SAFETY PROFILE OF A NEW TREATMENT DESIGNED WITH BMP4 OF STEMGEN, A 'KEY' PROTEIN ABLE TO BLOCK THE REPRODUCTION OF STEM CELLS IN BRAIN TUMOR. THE RESULTS OF PRE-CLINICAL RESEARCH SHOW A GOOD TOXICITY PROFILE AND SUGGEST BMP4 AS A POSSIBLE INNOVATIVE BIOLOGICAL THERAPY AGAINST THE MOST AGGRESSIVE AND RESISTANT OF BRAIN TUMORS. Nerviano, March 27, 2015 - The... Read more
Four presentations from Nerviano Medical Sciences at the 2015 AACR meeting Nerviano, Italy, March 18th – Nerviano Medical Sciences will present four posters, one selected for an oral presentation, at the American Association for Cancer Research (AACR) Annual Meeting 2015, April 18 - 22, 2015, Pennsylvania Convention Center, Philadelphia, Pennsylvania. Read more
Tiziana Life Sciences licenses milciclib from Nerviano Medical Sciences London, 20 January 2015 – Tiziana Life Sciences plc (“Tiziana”, “the Company”, AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, is pleased to announce that it has exclusively licensed milciclib from Nerviano Medical Sciences Group (“Nerviano”), an Italian company dedicated to the discovery and development of... Read more
Il Prof. Carlo Croce, Vice Presidente con delega alla direzione scientifica di Nerviano, ambasciatore della ricerca italiana sul cancro al Quirinale al cospetto del Presidente della Repubblica Milano, 6 novembre 2014 – È toccato al Prof. Carlo Croce, Vice Presidente con delega alla direzione scientifica del Centro Ricerche di Nerviano (MI) e Direttore dell'Istituto di Genetica presso il Comprehensive Cancer Center dell’Ohio State University, il prestigioso ruolo di ambasciatore della ricerca italiana in ambito oncologico nel mondo al cospetto del Presidente della Repubblica Giorgio... Read more
Nerviano Medical Sciences discloses novel molecules suitable for the generation of antibody drug conjugates at the World ADC, San Diego (USA) 2014 Nerviano, November 6, 2014 - Nerviano Medical Sciences disclosed data on novel molecules suitable for the generation of antibody drug conjugates at the meeting World ADC San Diego (USA), 26-29 October 2014. Antibody drug conjugates (ADCs) represent a valuable approach to cancer therapy whereby antibodies are combined with potent cytotoxic compounds for selective tumor cell delivery and... Read more
Thymic carcinoma Phase II data of Milciclib, a kinase inhibitor discovered at Nerviano Medical Sciences, disclosed at the medical oncology meeting AIOM 2014           Nerviano, Italy – October 28, 2014 – Nerviano Medical Sciences announces that results from a single-arm Phase II study of Milciclib in patients with thymic carcinoma and thymoma were disclosed in a poster discussion session at the XVI Congresso Nazionale AIOM, October 24-26, 2014, Rome, Italy. This clinical trial represents collaborative work of Nerviano... Read more
Novel JAK2 inhibitors discovered by Nerviano Medical Sciences featured on the cover of Bioorganic & Medicinal Chemistry Nerviano - Italy, September 2014- Nerviano Medical Sciences researchers report the discovery, structure guided design, synthesis and biological evaluation of a novel class of JAK2 inhibitors on the journal Bioorganic & Medicinal Chemistry (“Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors”; Read more
   
Publications  
007  
   

Nerviano Medical Sciences

Nerviano Medical SciencesHeart of the innovative Group focused on the identification of new therapeutic strategies, research and development of new drugs, shapes the future of the oncology.

Read more...

Accelera

AcceleraAn Italian preclinical research Company, recognized and certified, all over the world provides high standard integrated services, with reliability and international compliance.

Read more...

CLIOSS

CliossWith an extensive experience, Clioss partners worldwide Biopharma, Biotech and Research Institutions for full cycle drug development from First-Time-In-Man.

Read more...

NerPharMa

NerpharmaConsolidated know-how, the highest quality standards characterize the offered services: for the formulation, the recording and production of the active principle.

Read more...